Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. trimmed its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 93.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 18,261 shares of the company’s stock after selling 262,010 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Design Therapeutics were worth $113,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Invesco Ltd. acquired a new stake in Design Therapeutics during the 4th quarter valued at $71,000. China Universal Asset Management Co. Ltd. acquired a new stake in Design Therapeutics during the 4th quarter valued at $74,000. Kennedy Capital Management LLC acquired a new stake in Design Therapeutics during the 4th quarter valued at $88,000. Intech Investment Management LLC acquired a new position in Design Therapeutics during the 4th quarter worth $109,000. Finally, Wells Fargo & Company MN grew its holdings in Design Therapeutics by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 18,428 shares of the company’s stock worth $114,000 after acquiring an additional 4,013 shares in the last quarter. 56.64% of the stock is owned by institutional investors and hedge funds.

Design Therapeutics Price Performance

Shares of DSGN stock opened at $3.51 on Monday. The firm has a market cap of $199.26 million, a P/E ratio of -4.13 and a beta of 1.77. Design Therapeutics, Inc. has a 1-year low of $2.60 and a 1-year high of $7.77. The firm has a fifty day moving average of $3.88 and a two-hundred day moving average of $4.88.

Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, sell-side analysts expect that Design Therapeutics, Inc. will post -0.91 EPS for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.